[144] 10x Genomics, Inc. SEC Filing
Rhea-AI Filing Summary
10x Genomics (TXG) Form 144 notice shows a proposed sale of 22,037 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $295,516.17 and an approximate sale date of 08/22/2025 on NASDAQ. The filing reports the shares were acquired as a Restricted Stock Unit grant on 08/21/2025 with 61,587 units noted as acquired and payment described as Services Rendered. It also discloses a prior sale by the same person of 4,044 shares on 05/22/2025 for gross proceeds of $33,562.37. The filer affirms no undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider plans to sell 22,037 shares (value $295.5k) from an RSU grant received one day earlier; prior small sale of 4,044 shares noted.
The filing documents a routine Rule 144 notice for the sale of common stock through a broker, indicating the shares originate from a restricted stock unit grant dated 08/21/2025 and are to be sold on 08/22/2025. The disclosure includes a recent small sale on 05/22/2025, suggesting ongoing insider liquidity activity but does not provide context on ownership percentage or company-wide impact. No financial performance data or forward-looking statements are included.
TL;DR: Filing is a standard Rule 144 notification; signer attests no undisclosed material information and references a services-based RSU payment.
The notice follows regulatory requirements by identifying the broker, share counts, acquisition method (RSU grant), and recent disposals. The signing representation about material information and the inclusion of prior sales meet disclosure norms. The document does not reveal governance changes, contracts, or material events beyond the securities transactions.